Charles Duncan
Stock Analyst at Cantor Fitzgerald
(2.05)
# 1074
Out of 5,270 analysts
302
Total ratings
44.74%
Success rate
27.76%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
ACADIA Pharmaceutica... | Reiterates: Overweight | 28 28 | 18.14 | 54.36% | 21 | Feb 27, 2025 | |
Jazz Pharmaceuticals | Downgrades: Neutral | 140 150 | 140.19 | 7% | 6 | Feb 26, 2025 | |
Axsome Therapeutics | Reiterates: Overweight | 153 153 | 127.09 | 20.39% | 22 | Feb 19, 2025 | |
GH Research | Initiates Coverage On: Overweight | 14 | 9.13 | 53.34% | 1 | Feb 13, 2025 | |
Bright Minds Bioscie... | Initiates Coverage On: Overweight | n/a | n/a | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 17 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 7 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 4 4 | n/a | n/a | 9 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 51 58 | 32.21 | 80.07% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 48 43 | 34.1 | 26.1% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 130 130 | 131.27 | -0.97% | 21 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 155 155 | 114.47 | 35.41% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 35 35 | 15.12 | 131.48% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 11 13 | 4.69 | 177.19% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 34 34 | 22.32 | 52.33% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 330 330 | n/a | n/a | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 38 45 | n/a | n/a | 2 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 52 50 | 34.11 | 46.58% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 5 | 5.13 | -2.53% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 7 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 4 | 0.47 | 751.06% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 4 | 1.36 | 194.12% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 58 | 35.7 | 62.46% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 10 | n/a | n/a | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 110 | 1.18 | 9222.03% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 80 | 4.32 | 1751.85% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 172 | n/a | n/a | 12 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 3 | 1.08 | 177.78% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 16 11 | 8.27 | 33.01% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 9 12 | 6.78 | 76.99% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 146 168 | 7.84 | 2042.86% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 11 5 | n/a | n/a | 4 | Apr 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 2.01 | 895.02% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 200 | 18.2 | 998.9% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 52 | n/a | n/a | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 8 4 | 0.5 | 700% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 24 | 2.49 | 863.86% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 372 144 | 1.84 | 7726.09% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 26 | n/a | n/a | 1 | Sep 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 24 35 | n/a | n/a | 3 | Sep 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 3 4 | 1.72 | 132.56% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 408 480 | 4.62 | 10289.61% | 4 | May 19, 2020 |